[1] Leiba M, Kedmi M, Duek A,et al. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis[J].Br J Haematol,2014, 166(5): 702-710. [2] 刘洁.基于网络平台的延续性护理在多发性骨髓瘤患者中的应用效果[J].中华现代护理杂志,2016,22(22):3147-3151. [3] 吴肖梅,韦英成,黄珍,等.医护一体化管理模式对神经根型颈椎病患者依从性和疗效的影响[J].中西医结合护理(中英文),2016,2(4):24-27. [4] 杨便红,王秋梅,闫岩,等.多发性骨髓瘤患者骨病自我管理调查及护理干预实践[J].中国护理管理,2013,13(6):86-88. [5] Buyukkarmikli NC, de Groot S, Fayter D,et al.Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal [J].Pharmacoeconomics,2018, 36(2): 145-159. [6] 闫岩,耿传营,左丽宏.多学科使用延续性护理在多发性骨髓瘤患者中的应用效果[J].中华现代护理杂志,2017,23(14):1843-1847.